PDRN has a deeper medical and regenerative literature than its current skincare popularity might suggest, but route of administration matters enormously.
Some of the strongest human evidence for PDRN comes from wound-healing research, not cosmetics. In a randomized clinical trial involving chronic diabetic foot ulcers, PDRN given by intramuscular and perilesional injection improved complete healing rates and wound closure compared with placebo over eight weeks. That is meaningful evidence for the biological activity of PDRN, but it is not evidence that a topical facial serum produces the same effect.
The evidence becomes more directly relevant to skincare when we look at skin-cell and tissue models. In research using PDRN isolated from Panax ginseng adventitious roots, the material increased keratinocyte and fibroblast proliferation and upregulated markers associated with extracellular matrix support and barrier function. The same study also demonstrated barrier-related effects in a 3D skin model and linked the response to adenosine A2A signaling.
That is particularly important for us because it means plant-derived PDRN is no longer just a sourcing concept. Ginseng-derived PDRN has its own experimental skin biology behind it. What it does not yet have is the depth of human topical data accumulated around more established cosmetic ingredients.
Topical evidence is beginning to emerge for the category. A 2025 study of low-molecular-weight PDRN derived from Paeonia lactiflora found that topical use improved barrier recovery after experimentally induced skin damage in a small human study of 10 participants, and also reported improvement in periorbital elasticity. That study used peony-derived PDRN, not the ginseng-derived material we formulate with, so we treat it as supportive evidence for the topical potential of plant-derived PDRN rather than proof for our specific raw material.
Delivery remains one of the biggest unanswered formulation questions. PDRN is not a tiny conventional active, and researchers continue to investigate ways to improve its movement through skin. In one study, nanoliposomal PDRN increased both skin permeation and retention compared with free PDRN, reinforcing the point that the vehicle matters when the molecule is this complex.
Our read of the evidence: PDRN has credible regenerative biology, strong mechanistic support, meaningful therapeutic evidence by injection, increasingly persuasive skin-model data, and an emerging but still limited topical human literature. The evidence for ginseng-derived topical PDRN specifically is promising, not finished.
That is exactly how we formulate with it: interested enough to take it seriously, disciplined enough not to borrow claims from an injection and paste them onto a serum.
The science is ahead of the marketing in some places and behind it in others. Our job is to know which is which.